BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31519579)

  • 1. Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Belt P; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4781-4786. PubMed ID: 31519579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
    Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
    Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.
    Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
    Anticancer Res; 2021 Dec; 41(12):5865-5871. PubMed ID: 34848441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.
    Higuchi T; Oshiro H; Miyake K; Sugisawa N; Han Q; Tan Y; Park J; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Chawla SP; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4653-4657. PubMed ID: 31519563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
    Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Wu NF; Yamamoto J; Hamada K; Han Q; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1745-1751. PubMed ID: 33813378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
    Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Transl Oncol; 2019 Sep; 12(9):1257-1263. PubMed ID: 31299622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model.
    Oshiro H; Tome Y; Kiyuna T; Miyake K; Kawaguchi K; Higuchi T; Miyake M; Zang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Nelson SD; Li Y; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Tissue Cell; 2019 Jun; 58():17-23. PubMed ID: 31133242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.